Theravance Biopharma, Inc. · NASDAQ:TBPH
Theravance Biopharma — Merger or Acquisition (February 2018)
8 slides from Theravance Biopharma's merger presentation, Feb 7, 2018
Slide 1: Cautionary Statement Regarding Forward-Looking Statements
Cautionary Statement Regarding Forward-Looking Statements Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, the company cautions investors that any forward-looking statements or projections made by the company are subject to risks and uncertainties that m
Slide 2: Announcing Global Collaboration Agreement for TD-1473
Announcing Global Collaboration Agreement TD-1473: novel, oral, intestinally restricted pan-JAK inhibitor Includes related back-up compounds in gastrointestinal restricted JAK program Potential to treat a range of inflammatory intestinal diseases Including ulcerative colitis and Crohn’s disease Impa
Slide 3: TD-1473 Represents a Differentiated and Potential Breakthrough Approach to Treating IBD
IBD = Inflammatory Bowel Disease UC = ulcerative colitis TD-1473 Represents a Differentiated and Potential Breakthrough Approach to Treating IBD First cohort UC patients in Phase 1b study Data demonstrated localized biological target engagement, with minimal systemic exposure Clinical responses afte
Slide 4: Janssen Offers Significant Value to TD-1473
TD-1473 program will benefit from Janssen’s broad expertise in IBD IBD is a key area of focus End-to-end expertise Discovery Translational Development Regulatory Commercial Experienced in multiple IBD programs, across a range of mechanisms Flagship commercial brands in Immunology Janssen Offers Sign
Slide 5: Next Steps in Clinical Development of TD-1473
Next Steps in Clinical Development of TD-1473 Large, Phase 2b/3 adaptive design induction and maintenance study in ulcerative colitis Expect to initiate in 2H 2018 Phase 2b/3 design should expedite development path Leveraging Janssen expertise in design and conduct Expect to initiate in 2H 2018 Croh
Slide 6: Key Terms of TD-1473 Collaboration with Janssen
Significant economics reflective of the potential value of TD-1473 Up to $1B in payments to Theravance Biopharma, including $100M upfront $200M fee following completion of Phase 2 Crohn’s study and Phase 2b induction portion of UC study, if Janssen elects to enter into exclusive license Up to $700M
Slide 7: Potential to maximize value for Theravance Biopharma
Global Collaboration Agreement for TD-1473 Shared belief in TD-1473 as a localized medicine with potential to transform the treatment landscape in IBD Meaningful program enhancements for TD-1473 Accelerate clinical development; plan to advance UC and Crohn’s in parallel Apply Janssen expertise in IB
Slide 8: Potential to maximize value for Theravance Biopharma
Global Collaboration Agreement for TD-1473 Potential to maximize value of TD-1473 for Theravance Biopharma Theravance kt Biopharma AK. Janssen ile | ce gohmenfobiwen Medicines That Make a Difference” A Shared belief in TD-1473 as a localized medicine with potential to transform the treatment landsca
Theravance Biopharma — Merger or Acquisition (February 2018) on 6ix